Compass Therapeutics (CMPX) Corporate presentation summary

Corporate highlights and financial position

• Achieved primary endpoint in Phase 2/3 study for tovecimig in 2L biliary tract cancer (BTC), with key secondary endpoints expected late Q1 2026.

• 17.1% overall response rate (ORR) in 2L BTC, compared to 5% with FOLFOX; $1B+ US market opportunity in BTC.

• Three clinical candidates in pipeline, with PD-1xVEGF-A bispecific entering Phase 1.

• Cash runway into 2028 with ~$209M projected at year-end 2025.

Pipeline and clinical development

• Robust pipeline includes tovecimig (DLL4xVEGF-A), CTX-471 (CD137 agonist), CTX-8371 (PD-1xPD-L1), and CTX-10726 (PD-1xVEGF-A).

• Tovecimig demonstrated monotherapy and combination activity in multiple solid tumors, with expansion into CRC, gastric, ovarian, renal, and HCC planned.

• CTX-471 advancing to Phase 2 NCAM (CD56)+ basket study in H1 2026.

• CTX-8371 showed confirmed responses in NSCLC, TNBC, and HL; cohort expansion ongoing.

• CTX-10726 Phase 1 initiation expected Q1 2026, with preclinical data showing superior anti-tumor activity.

Tovecimig clinical data and market opportunity

• Phase 2/3 study in 2L BTC showed 17.1% ORR (p=0.031) for tovecimig + paclitaxel vs. 5.3% for paclitaxel alone.

• Safety profile consistent with prior studies; independent monitoring recommended continuation.

• PFS/OS data expected late Q1 2026; >20% OS at >18 months median follow-up as of Sept 2025.

• US BTC incidence projected to grow to ~34,000 by 2037, with >$1B market potential for 2L BTC.

• 85% of 2L BTC patients have no approved therapeutic alternative, highlighting significant unmet need.